Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Visa and Mastercard are expected to report higher quarterly profits this week on steady consumer spending, and analysts will ...

On Monday morning, analysts at Morgan Stanley and Oppenheimer are out with new price targets for the S&P 500, both pointing to strong corporate earnings — as well as trade deals, a strong U.S. economy ...

Oppenheimer Asset Management on Monday raised its year-end target for the S&P 500 index to 7,100, the highest among major ...

Oppenheimer raised the firm’s price target on A.O. Smith (AOS) to $88 from $82 and keeps an Outperform rating on the shares. The firm notes A.O.

Detailed price information for Integer Holdings Corp (ITGR-N) from The Globe and Mail including charting and trades.

Oppenheimer analyst Brian Nagel sees upside in Carvana stock to $450. CVNA is set to report its fiscal second-quarter ...

Analysts upgraded Carvana shares, arguing the company is a "digitally-driven disruptor" in the fractured used car market.

Carvana ( NYSE: CVNA) tracked higher on Friday after Oppenheimer boosted its rating on the auto retailer to Outperform after ...

In a recent market update, Boston Scientific’s financial trajectory got a new spin with Oppenheimer raising its price target ...

Oppenheimer upgraded Spotify (NYSE:SPOT) to Outperform with a $800 price target on strong upside from user growth, advertising monetization.Shares are up 1.7% at $685.78 on Thus. trading. Spotify ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $490.55, a high estimate of $555.00, and a low estimate of $371.00. This upward trend is evident, with the ...